SAN ANTONIO–(BUSINESS WIRE)–Howard Energy Partners (HEP) today announced that it has executed a definitive agreement to acquire Iron Horse Midstream (Iron Horse), a portfolio company of Sixth Street, expanding its position in the prolific Anadarko Basin. The acquisition is supported by multidecade customer contracts covering approximately 167,000 dedicated acres and builds on HEP’s strong foundation for long-term growth and value creation. With this transaction, HEP’s investment in Midcontine
Month: October 2026
FRISCO, Texas–(BUSINESS WIRE)– #healthcare–Valify, the leading purchased services technology platform for healthcare, has been named a finalist for Achievement in Innovation in D CEO’s 2026 Excellence in Healthcare Awards. This year’s finalists were selected from a competitive pool of over 200 nominations across the North Texas healthcare community. The recognition follows a period of significant growth and product innovation for Valify, as the company expanded its platform with AI capabilities to help ho
Dubai, Emirati Arabi Uniti–(BUSINESS WIRE)–Dubai Chambers ha lanciato Chamber AI Hub, il primo marketplace al mondo di AI agentica sviluppato da una camera di commercio, che consente alle imprese di Dubai di accedere ad agenti di IA pronti all’uso in grado di svolgere autonomamente una serie di attività amministrative e operative. Il marketplace offre attualmente 22 agenti IA specializzati in sette aree aziendali, ovvero compliance, approvvigionamento, operazioni, finanza, vendite, risorse um
Dubai, Verenigde Arabische Emiraten–(BUSINESS WIRE)–Dubai Chambers heeft Chamber AI Hub gelanceerd, ‘s werelds eerste marktplaats voor agentic AI die door een kamer van koophandel is ontwikkeld. Via het platform krijgen bedrijven in Dubai toegang tot kant-en-klare AI-agents die zelfstandig uiteenlopende administratieve en operationele taken uitvoeren. Op de marktplaats zijn momenteel 22 gespecialiseerde AI-agents beschikbaar voor zeven bedrijfsfuncties: compliance, inkoop, bedrijfsvoering, fi
NEW YORK–(BUSINESS WIRE)– FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Pzena Investment Management, LLC (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries mus
NEW YORK–(BUSINESS WIRE)–Trilantic North America has again been recognized by Inc. and GrowthCap for its continued commitment to partnering with founders, entrepreneurs and management teams to build and grow enduring businesses. For the sixth consecutive year, Trilantic North America has been named to Inc.’s 2026 Founder-Friendly Investors list, which recognizes private equity firms, venture capital firms and lenders with a demonstrated track record of supporting founder-led businesses. The a
悉尼–(BUSINESS WIRE)–(美国商业资讯)– 以AI为核心的全球技术研究与咨询公司Information Services Group（ISG，纳斯达克股票代码：III）今日发布的一份最新研究报告显示，亚太地区的企业和机构正以互联互通的Workday平台取代分散的传统财务和人力资本管理(HCM)系统，以便更全面地掌握运营情况。 《2026年ISG Provider Lens®Workday生态系统报告——亚太地区》发现，面对严重的技能人才短缺、各不相同的用工要求，以及日益壮大的数字原生员工群体的期待，雇主对一体化系统的需求不断增长。澳大利亚和日本的人才短缺尤为突出，企业希望借助具备消费级产品使用体验的技术系统，吸引并留住专业人才。亚太地区的企业和机构正整合人员与财务信息，使运营决策更加协调一致。采用Workday已不再只是部署技术，而是逐步发展为更广泛的业务转型。 ISG亚太区合伙人兼区域负责人Michael Gale表示：“亚太地区正成为推动Workday生态系统扩展和平台创新的重要力量。这里的企业希望建立统一的数字化核心平台，同时保留足够的灵活性，以适应各市场不同
27 October 2026
HARGREAVE HALE AIM VCT PLC
(the “Company”)
NAV announcement
As at close of business on 23 October 2026, the unaudited Net Asset Value (NAV) for Hargreave Hale AIM VCT plc was as follows:
NAV per Ordinary share of 1p – 31.87 pence.
END
For further information, please contact:
| Canaccord Genuity Asset Management Limited Abbe Martineau |
aimvct@canaccord.com +44 20 7523 4525 |
LEI: 213800LRYA19A69SIT31
eQ Plc Managers’ Transactions
27 October 2026 at 3:30 p.m.
Person subject to the notification requirement
Name: Privestment Oy
Position: Closely associated person
(X) Legal person (1):Person Discharging Managerial Responsibilities In Issuer
Name: Jouko Pölönen
Position: Chief Executive Officer
Issuer: eQ Oyj
LEI: 743700R4FA6AVH5J3D68
Notification type: INITIAL NOTIFICATION
Reference number: 177634/10/8
____________________________________________
Transaction date: 2026-10-26
Venue: NASDAQ HELSINKI LTD (XHEL)
Instrument type: SHARE
ISIN: FI0009009617
Nature of transaction: ACQUISITION
Transaction details
(1): Volume: 3485 Unit price: 8.2 EUR
(2): Volume: 4300 Unit price: 8.2 EUR
(3): Volume: 1184 Unit price: 8.2 EUR
(4): Volume: 329 Unit price: 8.2 EUR
(5): Volume: 2 Unit price: 8.2 EUR
(6): Volume: 113 Unit price: 8.2 EUR
(7): Volume: 587 Unit price: 8.2 EUR
Aggregated transactions (7):
Volume: 10000 Volume weighted average price: 8.2 EUR
eQ Plc
Additional information: Juha Surve, Group General Counsel, tel. +358 9 6817 8733
Distribution: Nasdaq Helsinki, www.eQ.fi
eQ is a Finnish group that concentrates on asset management and Corporate Finance business. eQ Asset Management offers a wide range of asset management services to both institutions and individuals. The assets managed by the Group total approximately EUR 13.9 billion. Advium Corporate Finance, which is part of the Group, offers services related to mergers and acquisitions, real estate transactions and equity capital markets. The parent company eQ Plc’s shares are listed on Nasdaq Helsinki. More information about the Group is available on our website www.eQ.fi.
GOBLET Cohort 4 demonstrates approximately 15-month median duration of response that exceeds historical results for approved second-line checkpoint inhibitor monotherapy
100% of responding patients survived for longer than one year
FDA Fast Track Designation and recent regulatory guidance support advancement toward registration and potential expansion into HPV-driven head and neck cancer
SAN DIEGO, Oct. 27, 2026 (GLOBE NEWSWIRE) — Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, today announced updated data from Cohort 4 of its Phase 1/2 GOBLET study evaluating pelareorep in combination with atezolizumab (Tecentriq®) in patients with second-line or later squamous cell anal cancer (“SCAC”).
Although median overall survival has not yet been reached, the median duration of response is approximately 15 months,1 which compares favorably with historical results of 9.5 months for U.S. Food and Drug Administration (“FDA”)-approved retifanlimab monotherapy in a similar patient population.2 Notably, all patients who responded to treatment survived beyond 12 months, including multiple patients surviving over 24 months.
These results provide encouraging evidence that pelareorep enhanced the clinical benefit of checkpoint inhibition in advanced SCAC, a disease in which more than 90% of cases are associated with human papillomavirus (“HPV”).
“We see anal cancer as the starting point for building a pelareorep plus checkpoint inhibitor platform across HPV-driven cancers,” said Jared Kelly, Chief Executive Officer of Oncolytics. “Our survival data and recent FDA regulatory clarity give us a path to pursue registration in anal cancer while expanding into other HPV-associated tumors, including head and neck cancer, where pelareorep has already demonstrated encouraging clinical activity.”
FDA Pathway Opens Door to Broader HPV Cancer Platform
Following recent FDA interactions and receipt of Fast Track Designation, Oncolytics plans to explore additional clinical studies with a potential checkpoint inhibitor partner to support registrational development in SCAC. The Company believes that durable clinical responses may support an accelerated approval pathway, while overall survival could provide evidence of clinical benefit supporting full approval, subject to FDA agreement.
The Company also sees potential to expand into HPV-associated head and neck squamous cell carcinoma. HPV accounts for approximately 70% of oropharyngeal cancers in the United States, representing a substantial patient population where checkpoint inhibitors are already established therapies.
Pelareorep has previously demonstrated signals of antitumor activity in head and neck cancer studies, although it has not yet been evaluated in combination with a checkpoint inhibitor in this disease. Oncolytics may explore initiating such a combination study in the near term as part of its broader HPV-driven cancer strategy.
About GOBLET
The GOBLET (Gastrointestinal tumOrs exploring the treatment comBinations with the oncolytic reovirus peLarEorep and anTi-PD-L1) study is a phase 1/2 multiple indication study in advanced or metastatic gastrointestinal tumors. The study is being conducted at 17 centers in Germany and is being managed by AIO-Studien-gGmbH (“AIO”). The co-primary endpoints of the study are objective response rate and/or disease control rate and safety. Key secondary and exploratory endpoints include additional efficacy assessments and evaluation of potential biomarkers. The study comprises five treatment groups:
- Pelareorep in combination with atezolizumab, gemcitabine, and nab-paclitaxel in first-line advanced/metastatic pancreatic cancer patients;
- Pelareorep in combination with atezolizumab in first-line MSI (microsatellite instability)-high metastatic colorectal cancer patients;
- Pelareorep in combination with atezolizumab and TAS-102 in third-line metastatic colorectal cancer patients
- Pelareorep in combination with atezolizumab in second-line advanced and unresectable anal cancer patients; and
- Pelareorep in combination with mFOLFIRINOX with and without atezolizumab in newly diagnosed metastatic PDAC patients.
About AIO
AIO emerged from the study center of the medical oncology working group within the German Cancer Society. AIO operates with a non-profit purpose of promoting science and research with a focus on medical oncology. Since its foundation, AIO has become a successful sponsor and study management company and has established itself both nationally and internationally.
About Pelareorep
Pelareorep is an intravenously delivered, systemically active, investigational immunotherapy with a dual mechanism of action that selectively replicates in tumor cells while activating both innate and adaptive anti-tumor immune responses, including the upregulation of key inflammatory cytokines resulting in the formation of tertiary lymphoid structures and the expansion of tumor-infiltrating lymphocytes. It has been administered to over 1,200 patients, and clinical studies have demonstrated pelareorep’s potential to enhance the activity of checkpoint inhibitors and other anti-cancer therapies across multiple solid tumor types.
About Oncolytics Biotech Inc.
Oncolytics is a clinical-stage biotechnology company developing pelareorep, an investigational intravenously delivered double-stranded RNA immunotherapeutic agent. Pelareorep has demonstrated encouraging results in multiple first-line pancreatic cancer studies, two randomized Phase 2 studies in metastatic breast cancer, and early-phase studies in anal and colorectal cancer. It is designed to induce anti-cancer immune responses by converting immunologically inactive tumors to active through the activation of innate and adaptive immune responses.
The Company is advancing pelareorep in combination with chemotherapy and/or checkpoint inhibitors in metastatic gastrointestinal cancers, where pelareorep has received Fast Track designation from the FDA for colorectal, anal, and pancreatic cancer. Oncolytics is actively pursuing strategic partnerships to accelerate development and maximize commercial impact. For more about Oncolytics, please visit: www.oncolyticsbiotech.com or follow the Company on LinkedIn and on X @oncolytics.
Tecentriq® (atezolizumab) is a registered trademark of Genentech, a member of the Roche Group.
References
- GOBLET Cohort 4 efficacy estimates supplied from internal calculations for this draft
- Rao S, et al. Phase II study of retifanlimab in patients (pts) with squamous carcinoma of the anal canal (SCAC) who progressed following platinum-based chemotherapy. Annals of Oncology. 2020 September. doi: https://doi.org/10.1016/j.annonc.2020.08.2272
Forward-looking statements
This press release contains forward-looking statements, within the meaning of Section 21E of the U.S. Securities Exchange Act of 1934, as amended, and forward-looking information under applicable Canadian securities laws (such forward-looking statements and forward-looking information are collectively referred to herein as “forward-looking statements”). Forward-looking statements contained in this press release include statements regarding beliefs as to the potential, registration, mechanism of action and benefits of pelareorep as a cancer therapeutic; the results, and implication of results, from Cohort 4 of the GOBLET study; the Company’s plans to explore additional clinical studies related to SCAC and its beliefs in their potential benefits; the Company’s possible expansion into HPV-associated head and neck cancer including a study in combination with pelareorep; the Company’s goals, strategies, and objectives; the Company’s belief in the clinical promise of pelareorep in anal, colorectal, pancreatic and other gastrointestinal cancers; and the Company’s goals and expectations for its potential registrational development path for pelareorep in multiple gastrointestinal cancers. In any forward-looking statement in which Oncolytics expresses an expectation or belief as to future results, such expectations or beliefs are expressed in good faith and are believed to have a reasonable basis, but there can be no assurance that the statement or expectation or belief will be achieved. These statements involve known and unknown risks and uncertainties that may cause actual results to differ materially from those anticipated. These risks include, but are not limited to, regulatory outcomes, trial execution, financial resources, access to capital markets, and market dynamics. Please refer to Oncolytics’ public filings with securities regulators in the United States and Canada for more information. The Company assumes no obligation to update forward-looking statements, except as required by law.
Company Contact
Jon Patton
Director of IR & Communication
jpatton@oncolytics.com
